

# Michael Krainer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5751293/publications.pdf>

Version: 2024-02-01

29  
papers

1,966  
citations

686830

13  
h-index

552369

26  
g-index

31  
all docs

31  
docs citations

31  
times ranked

3740  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 700-712.           | 5.1 | 1,280     |
| 2  | Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.   | 0.8 | 202       |
| 3  | Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020, 78, 822-830.  | 0.9 | 99        |
| 4  | HIF1 $\alpha$ Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells. <i>Molecular Cancer Research</i> , 2015, 13, 556-564.  | 1.5 | 77        |
| 5  | Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells. <i>International Journal of Cancer</i> , 2015, 137, 1330-1340.                               | 2.3 | 38        |
| 6  | Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. <i>Oncotarget</i> , 2018, 9, 812-823.  | 0.8 | 35        |
| 7  | Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 309-315.  | 2.0 | 32        |
| 8  | Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , 2018, 1, 467-475.   | 2.6 | 25        |
| 9  | Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , 2015, 33, 139-139. | 0.8 | 25        |
| 10 | Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives. <i>Oncolmunology</i> , 2019, 8, e1644109.   | 2.1 | 23        |
| 11 | Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 1056-1065.  | 1.0 | 20        |
| 12 | Synthetic lethality guiding selection of drug combinations in ovarian cancer. <i>PLoS ONE</i> , 2019, 14, e0210859.  | 1.1 | 16        |
| 13 | The prostate cancer landscape in Europe: Current challenges, future opportunities. <i>Cancer Letters</i> , 2022, 526, 304-310.   | 3.2 | 16        |
| 14 | Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 548.  | 1.7 | 13        |
| 15 | Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2018, 97, 41-48.   | 1.3 | 9         |
| 16 | A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients With Androgen Independent Prostate Cancer. <i>Journal of Urology</i> , 2007, 177, 2141-2145.   | 0.2 | 7         |
| 17 | The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma. <i>PLoS ONE</i> , 2015, 10, e0133838.   | 1.1 | 7         |
| 18 | Impact of frailty on the management of patients with gynecological cancer aged 80 years and older. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 557-563.  | 0.8 | 6         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment. <i>Oncotarget</i> , 2018, 9, 16197-16204.  | 0.8 | 6         |
| 20 | Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. <i>European Journal of Cancer</i> , 2020, 125, 153-163.               | 1.3 | 5         |
| 21 | Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer. <i>Translational Research</i> , 2021, 230, 21-33.   | 2.2 | 5         |
| 22 | The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166. | 2.0 | 4         |
| 23 | LUBAC and ABIN-1 Modulate TRAIL-Based NF- $\kappa$ B Induction in Human Embryonic Kidney 293 Cells. <i>BioResearch Open Access</i> , 2018, 7, 81-89.  | 2.6 | 4         |
| 24 | Circulating Endothelial Progenitor Cells in Castration Resistant Prostate Cancer: A Randomized, Controlled, Biomarker Study. <i>PLoS ONE</i> , 2014, 9, e95310.   | 1.1 | 4         |
| 25 | Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020, 5, e000880.   | 2.0 | 4         |
| 26 | Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast. <i>Oncotarget</i> , 2018, 9, 36379-36391.   | 0.8 | 3         |
| 27 | MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice. <i>Cancers</i> , 2022, 14, 749.   | 1.7 | 1         |
| 28 | 32nd International Austrian Winter Symposium. <i>EJNMMI Research</i> , 2016, 6, 32.   | 1.1 | 0         |
| 29 | A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions. <i>Journal of Visualized Experiments</i> , 2021, , .   | 0.2 | 0         |